ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2713

Is Effectiveness of Immunosuppression for Interstitial Lung Disease in Systemic Sclerosis (SSc) Modified By Lung Disease Severity or SSc Duration?

Sabrina Hoa1, Sasha Bernatsky2, Russell Steele3 and Marie Hudson1, 1Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, 2Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 3Department of Mathematics and Statistics, McGill University, Montreal, QC, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: immunosuppressants, interstitial lung disease and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Sclerosis and Related Disorders – Clinical Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in SSc. Immunosuppression is used to treat ILD, but little is known about its benefits in mild ILD or late SSc, as these patients were excluded from randomized trials. Our aim was to determine if, in SSc patients with incident ILD, the effectiveness of immunosuppression was differential according to ILD severity and SSc duration.

Methods: We studied all SSc patients with incident ILD, using data from the Canadian Scleroderma Research Group registry (> 98% met 2013 ACR/EULAR classification criteria for SSc). The primary exposure was time dependent ever/never exposure to methotrexate, cyclophosphamide, mycophenolate, azathioprine and/or cyclosporin A. The primary outcome was progression-free survival, with clinically meaningful progression defined as >10% decline in forced vital capacity (FVC), or >5% to <10% decline in FVC and >15% decline in diffusion capacity of lung for carbon monoxide (DLCO) (OMERACT CTD-ILD 2015). Using ILD diagnosis as time zero, time to progression or death was compared between exposed and unexposed subjects. A marginal structural Cox model with inverse probability of treatment weights and multiple imputation was used to account for potential confounding and for missing data, respectively. Weights were constructed using age at baseline, sex, race, disease subtype (diffuse vs limited), and autoantibodies. Mild ILD was defined as FVC >80% predicted, and late SSc duration was defined as >7 years since first non-Raynaud. Our final model also adjusted for age, sex, race, disease subtype, and autoantibodies. Interaction terms were examined to determine if immunosuppression effectiveness differed in mild vs moderate/severe ILD, or in late vs early SSc. Subjects were censored at the visit when the outcome (death or progression) was first recorded, lost to follow-up or at last study visit.

 

Results: There were 204 SSc patients with incident ILD; 67 were exposed to immunosuppression at time zero or during follow up and 134 remained unexposed throughout follow-up (Table 1). In our models, subjects exposed to immunosuppression tended to have a lower estimated risk of progression or death versus unexposed subjects: weighted hazard ratio (HR) 0.65 (95% CI 0.34, 1.25). We were unable to detect a differential effect of immunosuppression according to ILD severity or SSc duration (p=0.24 and p=0.85 for interaction terms, respectively).

Conclusion: We were unable to detect a differential effect of immunosuppression according to ILD severity or SSc duration; this may be due to lack of power. A larger sample would be required to resolve this uncertainty and answer the important clinical question of whether SSc patients perceived to be at increased risk of progressive ILD, even if mild or later in the disease course, benefit from immunosuppression.

 

Table 1. Baseline characteristics of the cohort, stratified by exposure status

 

Never-exposed to treatments (N=134)

Ever-exposed to treatments (N=67)

 

Mean (SD) or N (%)

Missing

(%)

Mean (SD) or N (%)

Missing

(%)

Age, years

60.5 (10.7)

–

53.6 (12.6)

–

Female

122 (89.1%)

–

56 (83.6%)

–

White

97 (73.5%)

4

44 (67.7%)

3

Smoking (ever vs. never)

 75 (59.1%)

7

39 (63.9%)

9

Disease duration from 1st non-RP

14.2 (10.0)

–

9.2 (7.8)

–

Diffuse subtype (vs. limited)

 62 (45.3%)

–

49 (73.1%)

–

Modified Rodnan skin score (0-51)

9.5 (8.5)

2

13.8 (11.4)

1

Anti-centromere

 50 (39.7%)

8

10 (15.6%)

4

Anti-topoisomerase 1

20 (15.9%)

8

15 (23.4%)

4

Anti-RNA polymerase III

19 (15.1%)

8

18 (28.1%)

4

Anti-Ro52/TRIM21

35 (27.8%)

8

14 (21.9%)

4

FVC, % predicted

90.8 (17.4)

16

84.8 (17.8)

19

TLC, % predicted

95.5 (16.6)

23

88.9 (14.4)

28

DLCO, % predicted

65.5 (19.4)

23

63.9 (22.8)

31

 


Disclosure: S. Hoa, None; S. Bernatsky, None; R. Steele, None; M. Hudson, None.

To cite this abstract in AMA style:

Hoa S, Bernatsky S, Steele R, Hudson M. Is Effectiveness of Immunosuppression for Interstitial Lung Disease in Systemic Sclerosis (SSc) Modified By Lung Disease Severity or SSc Duration? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/is-effectiveness-of-immunosuppression-for-interstitial-lung-disease-in-systemic-sclerosis-ssc-modified-by-lung-disease-severity-or-ssc-duration/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-effectiveness-of-immunosuppression-for-interstitial-lung-disease-in-systemic-sclerosis-ssc-modified-by-lung-disease-severity-or-ssc-duration/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology